Generali Asset Management SPA SGR Has $1.29 Million Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Generali Asset Management SPA SGR lifted its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 16.9% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 14,110 shares of the medical equipment provider’s stock after purchasing an additional 2,042 shares during the quarter. Generali Asset Management SPA SGR’s holdings in Zimmer Biomet were worth $1,287,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Garde Capital Inc. acquired a new position in shares of Zimmer Biomet in the 1st quarter valued at approximately $29,000. Washington Trust Advisors Inc. acquired a new position in shares of Zimmer Biomet in the 1st quarter valued at approximately $30,000. Columbia River Financial Group LLC acquired a new position in shares of Zimmer Biomet in the 1st quarter valued at approximately $30,000. Accent Capital Management LLC acquired a new position in shares of Zimmer Biomet in the 1st quarter valued at approximately $35,000. Finally, Cullen Frost Bankers Inc. grew its position in shares of Zimmer Biomet by 1,452.4% in the 1st quarter. Cullen Frost Bankers Inc. now owns 326 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 305 shares during the period. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, SVP Lori Winkler sold 1,500 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the sale, the senior vice president owned 6,833 shares in the company, valued at approximately $711,656.95. This represents a 18.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.39% of the company’s stock.

Zimmer Biomet Trading Up 2.1%

NYSE ZBH opened at $102.00 on Friday. The company has a market cap of $20.21 billion, a PE ratio of 24.82, a PEG ratio of 2.30 and a beta of 0.67. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54. Zimmer Biomet Holdings, Inc. has a 12 month low of $89.22 and a 12 month high of $114.72. The stock has a 50 day moving average of $101.74 and a 200-day moving average of $97.88.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, beating the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The company had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.06 billion. During the same quarter in the prior year, the firm posted $2.01 EPS. The firm’s revenue for the quarter was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio is 23.36%.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on ZBH shares. Rothschild Redb raised Zimmer Biomet to a “strong-buy” rating in a research report on Thursday, September 18th. Rothschild & Co Redburn started coverage on Zimmer Biomet in a research report on Thursday, September 18th. They set a “buy” rating and a $130.00 price target for the company. UBS Group upped their price target on Zimmer Biomet from $91.00 to $96.00 and gave the stock a “sell” rating in a research report on Friday, August 8th. Redburn Partners set a $130.00 price target on Zimmer Biomet in a research report on Thursday, September 18th. Finally, Stifel Nicolaus upped their price target on Zimmer Biomet from $115.00 to $118.00 and gave the stock a “buy” rating in a research report on Friday, September 19th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $111.94.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.